Implementing a new outpatient ambulatory pathway for AML
Research type
Research Study
Full title
Implementing a new outpatient ambulatory pathway for high intensity therapy for acute myeloid leukaemia (AML). A qualitative study exploring the perspectives of patients and informal carers.
IRAS ID
343103
Contact name
Sara Wills Percy
Contact email
Sponsor organisation
University of Surrey
Duration of Study in the UK
0 years, 2 months, 4 days
Research summary
This research project aims to explore the views and lived experiences of patients and their families after completing intensive induction and consolidation chemotherapy for acute myeloid leukaemia on a newly implemented ambulatory outpatient pathway. The study will seek to understand the perceived impact of receiving therapy via this new pathway and the views and recommendations of patients and their families around what additional support and changes they would have found helpful during this process in order to improve the service provided via this pathway. Results of this study will be used to inform future research and change future practice.
REC name
London - Queen Square Research Ethics Committee
REC reference
24/PR/1070
Date of REC Opinion
5 Nov 2024
REC opinion
Further Information Favourable Opinion